Topical alprostadil cream for the treatment of erectile dysfunction: A combined analysis of the Phase II program

Urology

Volumn 60, Issue 6, 2002, Pages 1077-1082

  Steidle, Christopher ^a,b,c,d   Padma Nathan, Harin ^a,b,c,d   Salem, Shawki ^a,b,c,d   Tayse, Natalie ^a,b,c,d   Thwing, Denise ^a,b,c,d   Fendl, Jane ^a,b,c,d   Yeager, James ^a,b,c,d   Harning, Ronald ^a,b,c,d  

^a Northeast Indiana Urology   (United States)

^b Male Clinic   (United States)

^c Symbiance Inc   (United States)

^d NexMed USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENETRATION ENHANCING AGENT; PLACEBO; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DIAGNOSTIC PROCEDURE; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PENIS ERECTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TIME;

ADMINISTRATION, TOPICAL; ADULT; AGED; ALPROSTADIL; ANALYSIS OF VARIANCE; CLINICAL TRIALS, PHASE II; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; VASODILATOR AGENTS;

EID: 0036897913     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01980-5     Document Type: Article

References (21)

1. Impotence. JAMA. 270:1993;83-90.
2. Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States prevalence and predictors . JAMA. 281:1999;537-544.
3. Johannes C.B., Araujo A.B., Feldman H.A., et al. Incidence of erectile function in men 40-69 years old longitudinal results from the Massachusetts Male Aging Study . J Urol. 163:2000;460-463.
4. Lue T.F. Erectile dysfunction. N Engl J Med. 342:2000;1802-1813.
5. Levine L.A. Diagnosis and treatment of erectile dysfunction. Am J Med. 109:2000;3S-30S.
6. Melman A., Rehman J. Pathophysiology of erectile dysfunction. Mol Urol. 3:1999;87-102.
7. Physician's Desk Reference: Caverject® Sterile Powder (Package Insert). Montvale, NJ, Medical Economics Company, 1999, pp 2458-2459.
8. Physician's Desk Reference: MUSE® (Package Insert). Montvale, NJ, Medical Economics Company, 1999, pp 3189-3190.
9. Shabsigh R., Padma-Nathan H., Gittleman M., et al. Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology. 55:2000;477-480.
10. Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impotence Res. 12:2000;S91-S100.
11. Richter S., Vardi Y., Ringel A., et al. Intracavernous injections still the gold standard for treatment of erectile dysfunction . Int J Impotence Res. 13:2001;172-175.
12. Vardi Y., Sprecher E., Gruenwald I. Logistic regression and survival analysis of 450 impotent patients treated with injection therapy long-term dropout parameters . J Urol. 163:2000;467-470.
13. 1 for the treatment of erectile dysfunction. J Urol. 153:1995;1828-1830.
14. Montorsi F., Guazzoni C., Barbieri L., et al. Clinical and hemodynamic effects of transdermal alprostadil for mild arteriogenic impotence a double-blind placebo controlled study . Int J Impotence Res. 7:1995;10-11.
15. Goldstein I., Payton T.R., Schechter P.J. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction. Urology. 57:2001;301-305.
16. Rosen R.C., Riley A., Wagner G., et al. The International Index of Erectile Function (IIEF) a multidimensional scale for assessment of erectile dysfunction . Urology. 49:1997;822-830.
17. Goldstein I., Lue T.F., Padma-Nathan H., et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
18. Padma-Nathan H., McMurray J.G., Pullman W.E., et al. On-demand IC351 (Cialis™) enhances erectile function in patients with erectile dysfunction. Int J Impotence Res. 13:2001;2-9.
19. Lewis R., Bennett C., Borkon W.D., et al. Patient and partner satisfaction with Viagra (sildenafil) treatment as determined by the erectile dysfunction inventory of treatment satisfaction questionnaire. Urology. 57:2001;960-965.
20. Dinsmore W.W., Hodges M., Hargreaves C., et al. Sildenafil citrate (Viagra) in erectile dysfunction near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects . Urology. 53:1999;800-805.
21. Porst H., Rosen R., Padma-Nathan H., et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction the first at-home clinical trial . Int J Impotence Res. 13:2001;192-199.